Bausch + Lomb (BLCO) Competitors

Zimmer Biomet (NYSE:ZBH) and Bausch + Lomb (NYSE:BLCO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, media sentiment, earnings, valuation, risk and analyst recommendations.

Is ZBH or BLCO more profitable?

Zimmer Biomet has a net margin of 11.86% compared to Bausch + Lomb's net margin of -7.50%. Zimmer Biomet's return on equity of 12.73% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zimmer Biomet	11.86%	12.73%	7.34%
Bausch + Lomb	-7.50%	2.62%	1.28%

Which has more volatility & risk, ZBH or BLCO?

Zimmer Biomet has a beta of 0.71, suggesting that its stock price is 29% less volatile than the S&P 500. Comparatively, Bausch + Lomb has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500.

Which has better earnings & valuation, ZBH or BLCO?

Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zimmer Biomet	$7.68B	2.42	$903.70M	$4.52	20.79
Bausch + Lomb	$4.79B	1.01	-$317M	-$1.03	-13.32

Do analysts rate ZBH or BLCO?

Zimmer Biomet presently has a consensus price target of $111.39, indicating a potential upside of 18.51%. Bausch + Lomb has a consensus price target of $15.45, indicating a potential upside of 12.68%. Given Zimmer Biomet's stronger consensus rating and higher probable upside, analysts plainly believe Zimmer Biomet is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zimmer Biomet	2 Sell rating(s)	9 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.35
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Do insiders and institutionals believe in ZBH or BLCO?

88.9% of Zimmer Biomet shares are held by institutional investors. Comparatively, 11.1% of Bausch + Lomb shares are held by institutional investors. 0.7% of Zimmer Biomet shares are held by insiders. Comparatively, 0.2% of Bausch + Lomb shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media prefer ZBH or BLCO?

In the previous week, Zimmer Biomet had 11 more articles in the media than Bausch + Lomb. MarketBeat recorded 14 mentions for Zimmer Biomet and 3 mentions for Bausch + Lomb. Bausch + Lomb's average media sentiment score of 0.82 beat Zimmer Biomet's score of 0.65 indicating that Bausch + Lomb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zimmer Biomet	5 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Bausch + Lomb	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zimmer Biomet beats Bausch + Lomb on 15 of the 16 factors compared between the two stocks.